Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First in Human, Open-label Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia

NCT03957915 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT03957915
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03957915 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First in Human, Open-label Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia
Lead sponsor
Institut Paoli-Calmettes
Phase
Phase 1
Overall status
Completed
Start date
May 29, 2020
Completion date
February 24, 2025
Enrollment
33 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia recurrent, acute lymphoblastic leukemia, in relapse, acute myeloid leukaemia recurrent, acute myeloid leukemia, in relapse, mixed phenotype acute leukemia